Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P31749 (
AKT
)
22,954
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MAX dimerization protein 1
(
MAD1
) is a transcription suppressor that antagonizes MYC-mediated transcription activation, and the inhibition mechanism occurs mainly through the competition of target genes' promoter MYC binding sites by
MAD1
. The promoter binding proteins switch between MYC and
MAD1
affects cell proliferation and differentiation. However, little is known about
MAD1
's regulation process in cancer cells. Here, we present evidence that
AKT
inhibits
MAD1
-mediated transcription repression by physical interaction with and phosphorylation of
MAD1
. Phosphorylation reduces the binding affinity between
MAD1
and its target genes' promoter and thereby abolishes its transcription suppression function. Mutation of the phosphorylation site from serine to alanine rescues the DNA-binding ability in the presence of activated
AKT
. In addition,
AKT
inhibits
MAD1
-mediated target genes (hTERT and ODC) transcription repression and promotes cell cycle and cell growth. However, mutated S145A
MAD1
abrogates the inhibition by
AKT
. Thus, our results suggest that phosphorylation of
MAD1
by
AKT
inhibits
MAD1
-mediated transcription suppression and subsequently activates the transcription of
MAD1
target genes.
...
PMID:The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. 1952 59